Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model
Carcinogenesis, Volume 35, No. 2, Article bgt321, Year 2014
Notification
URL copied to clipboard!
Description
In preclinical animal models, several phytochemicals have shown excellent potential to be used as effective agents in preventing and treating many cancers. However, the limited bioavailability of active agents could be one reason for their restricted usefulness for human consumption. To overcome this limitation, we recently introduced the concept of nanochemoprevention by encapsulating useful bioactive food components for their slow and sustained release. Here, we report the synthesis, characterization and efficacy assessment of a nanotechnology-based oral formulation of chitosan nanoparticles encapsulating epigallocatechin-3-gallate (Chit-nanoEGCG) for the treatment of prostate cancer (PCa) in a preclinical setting. Chit-nanoEGCG with a size of <200 nm diameter and encapsulating EGCG as determined by dynamic light scattering and transmission electron microscope showed slow release of EGCG in simulated gastric juice acidic pH and faster release in simulated intestinal fluid. The antitumor efficacy of ChitnanoEGCG was assessed in subcutaneously implanted 22R?1 tumor xenografts in athymic nude mice. Treatment with ChitnanoEGCG resulted in significant inhibition of tumor growth and secreted prostate-specific antigen levels compared with EGCG and control groups. In tumor tissues of mice treated with Chit-nanoEGCG, compared with groups treated with EGCG and controls, there was significant (i) induction of poly (ADP-ribose) polymerases cleavage, (ii) increase in the protein expression of Bax with concomitant decrease in Bcl-2, (iii) activation of caspases and (iv) reduction in Ki-67 and proliferating cell nuclear antigen. Through this study, we propose a novel preventive and therapeutic modality for PCa using EGCG that addresses issues related to bioavailability. © The Author 2013. Published by Oxford University Press. All rights reserved.
Authors & Co-Authors
Khan, Naghma A.
United States, Madison
University of Wisconsin-madison
Bharali, Dhruba Jyoti
United States, Albany
Albany College of Pharmacy and Health Sciences
Adhami, Vaqar M.
United States, Madison
University of Wisconsin-madison
Siddiqui, Imtiaz A.
United States, Madison
University of Wisconsin-madison
Cui, Huadong
United States, Albany
Albany College of Pharmacy and Health Sciences
Shabana, Sameh M.
Egypt, Mansoura
Faculty of Science
Mousa, Shaker A.
United States, Albany
Albany College of Pharmacy and Health Sciences
Mukhtar, Hasan
United States, Madison
University of Wisconsin-madison
Statistics
Citations: 186
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1093/carcin/bgt321
ISSN:
01433334
Research Areas
Cancer
Food Security
Health System And Policy